NCYT Stock Overview
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Novacyt S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.67 |
| 52 Week High | €0.86 |
| 52 Week Low | €0.36 |
| Beta | -1.71 |
| 1 Month Change | 51.41% |
| 3 Month Change | 29.97% |
| 1 Year Change | 28.60% |
| 3 Year Change | -86.92% |
| 5 Year Change | 252.63% |
| Change since IPO | 12.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| NCYT | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 19.6% | -1.9% | -0.9% |
| 1Y | 28.6% | -30.5% | -1.8% |
Return vs Industry: NCYT exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: NCYT exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| NCYT volatility | |
|---|---|
| NCYT Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NCYT's share price has been volatile over the past 3 months.
Volatility Over Time: NCYT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 120 | James McCarthy | www.novacyt.com |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt S.A. Fundamentals Summary
| NCYT fundamental statistics | |
|---|---|
| Market cap | UK£47.45m |
| Earnings (TTM) | -UK£25.30m |
| Revenue (TTM) | UK£7.87m |
6.0x
P/S Ratio-1.9x
P/E RatioIs NCYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NCYT income statement (TTM) | |
|---|---|
| Revenue | UK£7.87m |
| Cost of Revenue | UK£4.84m |
| Gross Profit | UK£3.03m |
| Other Expenses | UK£28.33m |
| Earnings | -UK£25.30m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 38.51% |
| Net Profit Margin | -321.40% |
| Debt/Equity Ratio | 0% |
How did NCYT perform over the long term?
See historical performance and comparison